PanOph

Salzmann Nodular Degeneration

Cornea

1. Clinical Analogy & Conceptual Overview

The Construction Analogy

Imagine the corneal epithelium as floor tiles laid over a smooth concrete base (Bowman's layer). In chronic inflammation or irritation, a rogue contractor (activated stromal keratocytes / myofibroblasts) burrows up beneath the tiles, depositing abnormal cement (collagen + proteoglycans) in irregular mounds. The tiles above don't break - they just dome upward. That is Salzmann Nodular Degeneration: sub-epithelial fibrocellular plaques that elevate the epithelium without perforating Bowman's layer, producing the characteristic grey-white nodules.

Historical Background

  • First described by Max Salzmann in 1925, the condition was initially described as a variety of nodular corneal dystrophy.
  • The term Salzmann nodular degeneration was adopted later to reflect its acquired degenerative nature.
  • Although chronic ocular-surface inflammation may be associated with secondary cases and has been proposed as a contributing mechanism, the condition is generally characterized as a non-inflammatory degeneration, and its pathogenesis remains incompletely understood.

Defining Characteristics (High-Yield Snapshot)

ParameterKey Fact
Nature• Non-inflammatory degeneration • May be associated with prior chronic ocular-surface inflammation, irritation, trauma, or surgery
Location• Sub-epithelial • Between the epithelium and Bowman’s layer
Material• Collagen types I, III, and V • Extracellular-matrix/ground-substance material • Myofibroblasts
Corneal zone• Mid-peripheral more commonly than central • May be clustered paracentrally
Bowman's layer• Fragmented or replaced beneath the nodule • Not necessarily intact
Epithelium• Generally remains intact • Thinned and attenuated over the nodule • Epithelial breakdown or defects can occur
Laterality• Bilateral in 72 of 108 patients (66.7%) in one retrospective series • May be asymmetric
Sex predilection• Female predominance • Approximately 2.7:1 female-to-male ratio in one retrospective series
Age• Predominantly sixth decade of life • Wide range reported, including approximately 13–92 years in one large retrospective series

2. Etiology & Predisposing Conditions

  • Salzmann nodular degeneration (SND) may be a secondary response to chronic ocular surface disease, although idiopathic cases also occur.
  • The unifying theme is chronic epithelial stress → epithelial-stromal interaction → myofibroblast activation; this is a proposed multifactorial mechanism.

Established Etiological Associations

CategorySpecific ConditionsMechanism
Inflammatory (reported associations)• Vernal keratoconjunctivitis • Phlyctenulosis/phlyctenular keratoconjunctivitis • Trachoma• Chronic ocular-surface inflammation or epithelial stress • Dysregulated wound healing, corneal remodeling, and subepithelial fibrosis
Mechanical/ Traumatic• Long-term contact-lens wear • Recurrent corneal erosions • Pterygium or other chronic ocular-surface irritation• Chronic mechanical irritation or epithelial microtrauma • Epithelial remodeling with subepithelial fibrosis or extracellular-matrix deposition
Degenerative• Corneal dystrophy or other corneal structural abnormalities• Chronic epithelial injury or mechanical disruption • Dysregulated wound healing, subepithelial fibrosis, and corneal remodeling
Post-surgical• Post-laser-assisted in situ keratomileusis (LASIK) • Post-photorefractive keratectomy (PRK) • Post-keratoplasty• Wound-healing dysregulation • Activated keratocytes or fibroblastic cells • Subepithelial extracellular-matrix deposition
Ocular-surface disease• Dry-eye disease• Tear-film instability and ocular-surface dryness • Chronic epithelial stress and irritation • Dysregulated corneal wound healing
Idiopathic• Many cases are primary or idiopathic • No recognized preceding keratitis or ocular-surface disorder• Possible subtle chronic epithelial microtrauma or subclinical ocular-surface inflammation • Proposed mechanism; not an established cause
EXAM TRAP
  • Meibomian gland dysfunction was the most common coexistent condition in a United States series. Contact lens wear, vernal keratoconjunctivitis (VKC), and trachoma are reported associations. Trachomatous keratitis was part of Salzmann’s original historical description.

3. Pathophysiology & Histopathology

Step 1 - Chronic Epithelial Injury

  • Recurrent epithelial stress, chronic irritation, or inflammation are proposed contributors to epithelial thinning, Bowman-layer disruption, and abnormal epithelial–stromal wound healing or remodeling; a direct causal relationship is not established.
  • Corneal epithelial injury can release interleukin-1 (IL-1), particularly interleukin-1 alpha (IL-1α)/interleukin-1 beta (IL-1β), and tumor necrosis factor alpha (TNF-α), which modulate corneal wound healing; specific release of these cytokines in Salzmann nodular degeneration has not been directly established.

Step 2 - Bowman's Layer Disruption

  • Bowman’s layer is focally fragmented or disrupted beneath the Salzmann nodule; the overlying epithelial basement membrane may show variable duplication.
  • This is a KEY histological finding: Bowman’s layer is commonly fragmented or absent beneath the nodule rather than preserved.

Step 3 - Myofibroblast Activation

  • Anterior stromal keratocytes can become activated fibroblasts/myofibroblasts in Salzmann nodular degeneration. Transforming growth factor beta 1 (TGF-β1) and other epithelial/stromal profibrotic signals are proposed contributors, but their primary causal role is not firmly established.
  • These cells are the workhorses of aberrant sub-epithelial matrix deposition.

Step 4 - Fibrocellular Plaque Formation

  • Myofibroblasts secrete a disorganised extracellular matrix containing collagen types I and III and fibronectin, contributing to nodule formation.

Step 5 - Epithelial Remodeling

  • The overlying epithelium becomes attenuated (thinned, not absent) and may show goblet cell metaplasia.
  • The surface becomes irregular, which can contribute to optical distortion and symptoms.

Histopathological Features

LayerHistological FindingSignificance
Epithelium• Attenuated/thinned with fewer cell layers. • Reported descriptions include fewer epithelial cell layers over the nodule; some specimens show only a single flattened layer. • Occasional goblet cell metaplasia was not verified.• May be irregular or may occasionally show fluorescein staining. • A specific causal link between epithelial thinning or goblet cell metaplasia and punctate staining is not established.
Sub-epithelial zone• Hypercellular or fibrocellular mound of extracellular matrix. • Located between the thinned epithelium and fragmented or absent Bowman’s layer. • PAS-positive, basement-membrane-like material has been reported.• Characteristic structural finding used in clinical and histopathologic recognition of Salzmann nodular degeneration. • The subepithelial location is diagnostically useful.
Bowman's layer• Fragmented, disrupted, or absent beneath the nodule. • May be partially replaced by granular periodic acid–Schiff-positive extracellular material resembling a basement membrane.• Bowman’s-layer disruption may be present in Salzmann nodular degeneration. • The distinction from band keratopathy should not rely on Bowman’s-layer change alone; correlate clinical morphology and histopathologic findings.
Anterior stroma• Activated stromal keratocytes/fibroblasts with myofibroblast characteristics have been described. • Alpha-smooth muscle actin expression was not verified in the reviewed primary histopathology evidence. • Disorganized or irregular collagen lamellae.• TGF-β1 and other wound-healing mediators have been proposed to promote fibroblast-to-myofibroblast activation and disorganized extracellular-matrix deposition. • TGF-β-directed therapy is not an established clinical treatment or validated therapeutic target for Salzmann nodular degeneration.
Collagen type• Abnormal extracellular-matrix deposition containing collagen types I and III has been reported. • Type V collagen in Salzmann nodules was not verified in the reviewed primary histopathology studies.• Associated with abnormal extracellular-matrix deposition and reparative stromal remodeling. • Not established as a validated biochemical marker of abnormal repair in Salzmann nodular degeneration.
Proteoglycans• Increased decorin or biglycan and altered keratan sulfate have not been verified in Salzmann nodular degeneration-specific studies.• Nodular or disorganized extracellular-matrix changes may contribute to anterior corneal surface irregularity and irregular astigmatism. • A proteoglycan-specific causal role in optical scatter or haze remains unverified.
Inflammatory cells• Variable findings: B- and T-cell lymphocytes have been described in some excised nodules. • Other descriptions report decreased cell density or little significant immune-cell infiltration.• Salzmann nodular degeneration is generally described as non-inflammatory or degenerative, although chronic ocular-surface inflammation may contribute to pathogenesis. • A uniform sparse-lymphocyte, generally hypocellular pattern and a ‘burned-out’ inflammation pattern are not established.
Exam pearl
  • The subepithelial fibrocellular tissue may stain positively for collagen with trichrome staining. Periodic acid–Schiff-positive, basement-membrane-like material may be present. Congo red-negative hyaline-like material has been reported, excluding amyloid.

4. Clinical Features

Symptoms

  • Foreign body sensation / irritation - most common presenting symptom
  • Reduced visual acuity - when nodules encroach on the visual axis or induce irregular astigmatism
  • Glare and monocular diplopia - due to irregular anterior surface
  • Photophobia - especially with associated surface disease
  • Recurrent erosion episodes - due to thin, vulnerable epithelium over nodules
  • Contact lens intolerance - may occur, particularly in contact lens wearers
  • Asymptomatic - most patients are asymptomatic; peripheral nodules are common

Slit-Lamp Examination - The 5 Critical Observations

FeatureDescriptionClinical Correlation
Nodule morphology• Discrete, slightly elevated, grey-white to bluish-white opacities • 0.5–2mm diameter each• Translucent quality due to fibrocellular material
Number• Few (3–5) to dozens • May coalesce• Severity correlates with visual impact
Location• Mid-peripheral paracentral annular arrangement • Occasionally central• Peripheral = less visual impact • Central = surgical candidate
Associated pannus• Superficial vascularization at base of nodule• Seen in ~40% • Correlates with preceding inflammation
Fluorescein sodium (NaFl) staining• Negative over nodule (elevated epithelium) • Positive at borders (thinned adjacent epithelium)• Irregular punctate staining pattern
Rose Bengal / lissamine green (LG)• Stains devitalized epithelial cells at nodule margins• Confirms epithelial compromise
Retroillumination• Best modality to count nodules • Best modality to assess optical zone involvement• Key for surgical planning
Surface regularity• Irregular astigmatism on keratoscopy • Placido ring distortion• Explains visual distortion disproportionate to opacity

Grading / Staging Systems

No universally accepted grading system exists. Clinically useful descriptors include:

GradeDescriptionVisual Impact
Mild• 1–5 small peripheral nodules • Outside 4 mm optical zone• Minimal • Often asymptomatic
Moderate• Multiple nodules • ≤4 mm zone • Some coalescence• Moderate irregular astigmatism • Contact-lens intolerance
Severe• Dense nodules ≥ central 4 mm • Coalescent plaques • Pannus• Significant best-corrected visual acuity (BCVA) reduction • Surgical indication
Exam pearl
  • Ring-like peripheral confluent nodules have been reported in Salzmann nodular degeneration (SND), but nodules are typically discrete.
  • Vernal keratoconjunctivitis is an associated chronic ocular-surface inflammatory condition in secondary Salzmann nodular degeneration.

5. Investigations

  • The investigation of Salzmann nodular degeneration (SND) is primarily clinical.
  • Ancillary tests confirm, characterize, and guide management:
InvestigationTechnique / FindingClinical Value
Slit-lamp biomicroscopy• Broad beam • Retroillumination • Sodium fluorescein (NaFl)• Primary diagnostic tool • Map nodules
Corneal topography (Placido-based)• Irregular astigmatism • Steepening over nodules • Disrupted mire rings• Quantify refractive impact • Preoperative baseline
Anterior segment optical coherence tomography (AS-OCT)• Hyperreflective subepithelial deposit • Epithelial thinning • Bowman's disruption • Precise depth mapping• Confirm subepithelial location • Gauge depth • Post-treatment follow-up
In vivo confocal microscopy (IVCM)• Hyperreflective subepithelial deposits • Activated keratocytes • Sub-basal nerve plexus disruption• Research tool • Provides noninvasive morphologic information • Correlates with histologic findings • Not a diagnostic substitute for histopathology
Corneal tonometry (air puff)• May give falsely low intraocular pressure (IOP) over elevated nodules• Awareness of artifact • Use Goldmann applanation tonometry or Pascal dynamic contour tonometry over unaffected cornea
Scheimpflug imaging (Pentacam)• Elevation maps • Pachymetry changes • Posterior float• Rule out ectasia (especially after contact-lens wear or refractive surgery)
Histopathology (excised tissue)• Periodic acid–Schiff (PAS) positive • Trichrome positive • Subepithelial fibrocellular tissue • Variable epithelial thinning • Bowman layer disruption or absence• Supports diagnosis in excised tissue • Correlate with clinical findings • Research/academic use
Impression cytology• Squamous metaplasia • Goblet cell reduction • Inflammatory cells• Assess ocular surface compromise

Anterior segment optical coherence tomography (AS-OCT) Findings - Exam Favourite

  • Hyperreflective sub-epithelial band between epithelium and anterior stroma
  • Focal epithelial thinning at nodule apex
  • Disruption/absence of Bowman's layer reflex beneath nodule
  • Normal posterior stroma - helps rule out deep stromal disease
  • Intraoperative optical coherence tomography (OCT) can delineate the cleavage plane between the nodule and underlying corneal tissue during image-guided lamellar keratectomy.
  • Postoperatively, optical coherence tomography (OCT) can document reduction or disappearance of nodules.
Exam pearl
  • On anterior segment optical coherence tomography (AS-OCT), the hyperreflective deposit in Salzmann nodular degeneration (SND) is ANTERIOR to the stroma (sub-epithelial).
  • Do not confuse with the hyperreflective anterior stromal haze of post-refractive surgery.
  • Do not confuse with the endothelial guttae signal in Fuchs endothelial corneal dystrophy (FECD) (posterior corneal surface).

6. Differential Diagnosis

Differential Diagnosis - Comparison Table
Differential Diagnosis - Comparison Table
FeatureSalzmann nodular degenerationBand keratopathyAnterior crocodile shagreenEpithelial basement membrane dystrophyLattice dystrophy grade II (Avellino)
Location• Subepithelial • Mid-peripheral or peripheral• Superficial/subepithelial • Interpalpebral• Deep epithelium and/or Bowman's layer• Epithelial basement membrane• Superficial/anterior stroma • Deeper stroma
Material• Collagenous fibrocellular/extracellular matrix • Disorganized collagen bundles• Calcium hydroxyapatite• Structural collagen abnormality described• Redundant or abnormal basement membrane material• Amyloid • Granular and lattice-like deposits
Bowman's• Replaced • Fragmented • Disrupted • Absent• Calcified granular deposits• Altered • May be irregular or focally ruptured• Intact• Disrupted or traversed by deposits
Staining: sodium fluorescein• Typically negative over intact epithelium • Epithelial defects may stain• Erosions or epithelial defects may stain • Band itself does not inherently stain• May become more apparent after fluorescein• Map-like changes may show negative staining • Erosions or defects may stain• Erosions or epithelial defects may stain
Staining special• Periodic acid–Schiff positive • Trichrome positive • Congo red negative• Von Kossa positive• Structural collagen abnormality described• Periodic acid–Schiff positive • Thickened, duplicated, or redundant basement membrane• Congo red positive • Thioflavin T may be positive but is not invariant
Visual impact• Irregular astigmatism • Haze • Visual distortion or decreased acuity• Horizontal interpalpebral plaque • May extend into the visual axis and reduce acuity• Usually minimal visual impact • Typically benign and asymptomatic• Recurrent erosions • Blurred or distorted vision may occur• Lattice lines • Progressive anterior stromal haze
Laterality• Often bilateral • Approximately 66%• Variable • May be bilateral in systemic or familial forms• Usually bilateral• Usually bilateral • Often asymmetric• Usually bilateral
Genetics• No single established causal gene • Multifactorial• Usually acquired • Associated with local ocular or systemic calcium/phosphate abnormalities • Rare familial forms occur• Usually degenerative or secondary • General autosomal dominant transforming growth factor beta-induced inheritance is not established• Not primarily a stromal genetic dystrophy • Involves the epithelial basement membrane• Autosomal dominant transforming growth factor beta-induced-associated • R124H variant • Also termed granular corneal dystrophy type 2
Treatment• Superficial keratectomy • Phototherapeutic keratectomy may be adjunctive• Ethylenediaminetetraacetic acid chelation • Superficial keratectomy and/or phototherapeutic keratectomy• Usually observation • No treatment generally required• Debridement • Diamond-burr polishing and/or phototherapeutic keratectomy• Phototherapeutic keratectomy for superficial deposits • Deep anterior lamellar keratoplasty or penetrating keratoplasty for deeper deposits
Exam pearl
  • Band keratopathy shows a lucent separation from the limbus and Swiss-cheese holes where corneal nerves traverse Bowman layer and interrupt calcium-phosphate deposition. Salzmann nodular degeneration (SND) nodules are discrete, elevated, and mid-peripheral; they are typically rounded or oblong and may become confluent, rather than forming the classic interpalpebral horizontal chalk-white band of band keratopathy.

7. Management

Management Algorithm

Clinical ScenarioManagement Strategy
• Asymptomatic • Peripheral nodules • No visual-axis involvement• Observation • Treat underlying disease, including vernal keratoconjunctivitis (VKC), dry eye, or contact-lens-related disease
• Symptomatic • Foreign-body sensation • No visual-axis involvement • Mild to moderate disease• Ocular lubricants • Anti-inflammatory treatment with ciclosporin or corticosteroid • Address underlying etiology • If contact-lens-related: contact lens holiday, refitting, or cessation
• Moderate-to-severe symptoms • Visual acuity affected • Irregular astigmatism • Failed conservative treatment• Surgical intervention indicated • Superficial keratectomy or phototherapeutic keratectomy (PTK)
• Dense pannus or vascularization at the nodule base• Address inflammation first • Consider preoperative anti-vascular endothelial growth factor (VEGF) adjunct • Then perform surgery
• Significant corneal haze remaining after superficial keratectomy• Phototherapeutic keratectomy (PTK) for significant residual corneal haze after superficial keratectomy
• Recurrence after surgery • Recurrence frequency is procedure- and follow-up-dependent• Recurrence after surgery: 0–31% • Identify and treat triggering etiology • Repeat phototherapeutic keratectomy (PTK) for visually significant recurrence • Consider intraoperative mitomycin C (MMC) adjunct; use for Salzmann nodular degeneration is off-label
  • A. Medical Management
  • Preservative-free lubricants - mainstay for symptomatic relief; reduce epithelial stress
  • Topical ciclosporin A 0.05% (Restasis) / 0.1% - for associated dry eye disease (DED); immunomodulatory therapy for ocular surface inflammation
  • Topical corticosteroids - short courses for associated ocular surface inflammation; monitor intraocular pressure (IOP)
  • Antihistamines / mast cell stabilisers - for associated vernal keratoconjunctivitis (VKC)
  • Contact lens (CL) modification - cessation or reduction of lens wear; review lens fit
  • Systemic doxycycline (subantimicrobial dose) - for associated meibomian gland dysfunction
  • Dietary/vitamin supplementation - Omega-3, Vitamin A (if deficient)
  • II Medical management does not reverse established nodules. It aims to slow progression, treat the underlying cause, and reduce surgical risk by optimising the ocular surface pre-operatively.
  • B. Surgical Management

Indications for Surgery

  • Significant reduction in best-corrected visual acuity attributable to nodular involvement of the visual axis or irregular astigmatism
  • Significant foreign-body sensation or discomfort unresponsive to conservative management
  • Progressive irregular astigmatism or surface irregularity causing visual impairment
  • Consider surgery for persistent symptoms or visual impairment despite conservative management; contact-lens cessation or refitting may be beneficial before surgery

Surgical Options - Comparative Analysis

ProcedureTechniqueAdvantagesDisadvantagesRecurrence
Manual Superficial Keratectomy• Manual separation with forceps or a surgical blade • Peeling the nodule from the corneal surface • Anesthesia selected according to patient cooperation• Manual dissection • No excimer laser • Lower cost than phototherapeutic keratectomy• Small risk of corneal haze • Skill-dependent • Incomplete removal possible• 22% (9 of 41 eyes; mean follow-up 20.2 months in one study) • Higher if the underlying etiology is untreated
Excimer Laser Phototherapeutic Keratectomy• 193-nanometre argon-fluoride excimer ablation after manual nodule removal or pannectomy • Smooths residual surface irregularity• Smooths the corneal surface • Precise excimer ablation • Improves corneal regularity• Refractive change, often a myopic shift in Salzmann nodular degeneration • Removes corneal tissue • Requires access to an excimer laser• 18% (4 of 22 eyes required repeat phototherapeutic keratectomy; mean follow-up 2.0 ± 1.8 years in one study) • Recurrence rates vary by study and follow-up; direct superiority over superficial keratectomy alone is not established
Superficial Keratectomy + Adjunct Mitomycin-C• Mitomycin-C at 0.02% may be applied intraoperatively for a controlled, procedure-specific duration • Irrigate thoroughly with balanced salt solution • Off-label use• Reduces keratocyte and myofibroblast activation • May reduce recurrence• Potential epithelial toxicity or delayed epithelial healing • Potential limbal stem-cell toxicity with unintended or excessive exposure • Risk depends on concentration, exposure time, and application technique• Evidence is limited to case-report and small retrospective data • Superiority and recurrence benefit are not established
Topography-guided Phototherapeutic Keratectomy• Customized ablation area based on lesion dimensions • Lesion depth measured with corneal optical coherence tomography• Targets the measured lesion area • May reduce unnecessary ablation and refractive impact• Expensive • Requires specific software or laser platformLower (emerging data)
Amniotic Membrane Transplantation• Used as an adjunct after superficial keratectomy • Sutured or glued onto the corneal surface during the healing phase• Promotes re-epithelialisation • Anti-inflammatory • May reduce scarring• Requires an additional graft procedureRecurrence-reduction benefit is not established; recurrence has been reported despite amniotic membrane transplantation.

Operative Pearls - Superficial Keratectomy

  • Use topical anesthesia, commonly with proparacaine, for many superficial keratectomy procedures; individualize anesthesia selection, with periocular or retrobulbar anesthesia considered when cooperation or procedural needs require it.
  • Use an operating microscope when appropriate for visualization; specific illumination settings and globe-stabilization devices should be selected according to the surgeon’s technique and case requirements.
  • Prefer blunt dissection when a surgical plane is available, using a blunt blade or suitable microsurgical instrument; use sharp dissection only when necessary to establish or complete the plane, with care to avoid unnecessary stromal entry.
  • Identify the nodule edge, establish the available plane between the lesion and Bowman’s layer, and peel along that plane using a direction adapted to the lesion and surrounding anatomy; avoid treating an inferior-to-superior direction as universal.
  • Do not attempt to reconstruct Bowman’s layer; it may be disrupted or fragmented beneath the nodule. Establish and remain in the available surgical plane to avoid unnecessary stromal dissection.
  • After removal, consider surface smoothing with an appropriate instrument or adjunctive phototherapeutic keratectomy when residual irregularity remains; individualize the ablation depth to the corneal findings and treatment goal.
  • Place a bandage contact lens after superficial keratectomy when indicated and remove it after epithelial healing is confirmed; duration should be individualized rather than fixed at 3–5 days.
  • Use postoperative topical antimicrobial prophylaxis and tailor anti-inflammatory treatment and lubrication to epithelial healing, ocular-surface status, and clinical follow-up.
  • Warn patients that refractive change may occur after removal of significant Salzmann nodular degeneration; the direction and magnitude are variable and should be assessed individually.
  • Avoid unnecessarily deep dissection into the anterior stroma, because it may create an artificial or partial lamellar plane and increase the risk of stromal haze, scarring, or irregular astigmatism. Remove the nodule along the available subnodular plane while preserving healthy corneal tissue; consider surface-smoothing treatment when clinically indicated.

Phototherapeutic Keratectomy (PTK) Technical Considerations

  • Masking agents (methylcellulose): filled into valleys around elevated nodules to level the surface before ablation - allows laser to preferentially ablate elevated areas
  • Depth of ablation: determined by nodule height; guided by preoperative anterior-segment optical coherence tomography (AS-OCT) measurements
  • Refractive shift: counsel that refractive change may occur; a myopic shift may occur in Salzmann nodular degeneration
  • Combined phototherapeutic keratectomy (PTK)–photorefractive keratectomy (PRK): possible in suitable refractive candidates - normalize surface then correct refractive error in same sitting
  • Post-phototherapeutic keratectomy (PTK) haze: shallow ablations have less haze; mitomycin C 0.02% has been used after phototherapeutic keratectomy (PTK) in selected cases

8. Recurrence, Prognosis & Outcomes

Recurrence Facts

ParameterData
Overall recurrence rate (superficial keratectomy alone)• 9 of 41 cases (22%) over a mean follow-up of 20.2 months.
Recurrence rate (superficial keratectomy + phototherapeutic keratectomy)• Reported recurrence rates vary by surgical series and follow-up duration. • A single 10–20% recurrence rate is not established.
Key risk factor for recurrence• Recurrence risk is associated with persistent or untreated ocular-surface disease, including dry eye, vernal keratoconjunctivitis, and ongoing contact-lens-related irritation or misuse. • This is an association rather than a proven universal predictor.
Time to recurrence• Reported timing varies; after superficial keratectomy with phototherapeutic keratectomy, recurrence has been reported during 1–24 months. • Another series reported a mean follow-up of 2.0 ± 1.8 years, with 18% requiring repeat phototherapeutic keratectomy. • A universal 12–24-month recurrence interval is not established.
Recurrence morphology• Recurrence may occur at the original site; published reports describe recurrence in the same locations. • Consistent evidence that recurrent nodules are smaller or arise at adjacent sites is insufficient.
Management of recurrence• Recurrence may be managed with repeat superficial keratectomy and/or phototherapeutic keratectomy, together with treatment of persistent underlying ocular-surface disease. • Adjunctive intraoperative mitomycin C may be considered in selected recurrent cases, but supporting evidence is limited.
Prognosis for vision• Visual prognosis is generally favorable after treatment. • In one phototherapeutic keratectomy series, vision improved in 86% of cases. • A general 80–90% rate of best-corrected visual acuity improvement after surgery is not established.
Exam pearl
  • Recurrence risk is associated with persistent or untreated ocular-surface disease; a single most important predictor is not established.
  • Continued ill-fitting rigid contact-lens wear may contribute to ocular-surface irritation and recurrence risk, but recurrence is not inevitable.
  • Counsel patients to address persistent ocular-surface disease and avoid ongoing contact-lens-related irritation, as these may contribute to recurrence risk.

9. Quick Revision - One-Page Summary

DomainHigh-Yield Facts
Definition• Secondary or primary subepithelial fibrocellular degeneration • Collagen types I and III with activated fibroblasts or myofibroblasts form deposits that may replace or disrupt Bowman's layer • The overlying epithelium is typically thinned
Etiology• Reported associations include vernal keratoconjunctivitis, contact-lens wear, trachoma, rosacea or blepharitis, dry eye disease, trauma, and previous ocular surgery • Exact causation and the proportion of idiopathic cases remain uncertain
Epidemiology• Female predominance • Bilateral involvement is common but not universal • Age distribution is bimodal, with reported peaks in the fifth and eighth or ninth decades • No universally recognized Mendelian inheritance pattern or causative gene has been established
Key Histology• Periodic acid–Schiff-positive and trichrome-positive subepithelial collagenous or fibrocellular material • Bowman's layer is fragmented or absent • Stromal cells show a fibroblast phenotype, including vimentin positivity • Congo-red, von Kossa, and alpha-smooth muscle actin results should not be stated universally without a specific verified study
Slit Lamp• Gray-white or bluish-white elevated subepithelial nodules, usually peripheral or mid-peripheral • Fluorescein staining is typically absent unless the overlying epithelium is disrupted • Adjacent peripheral vascularization or pannus may occur
Anterior-segment optical coherence tomography (OCT) finding• Hyperreflective subepithelial deposits or masses covered by a thin epithelium • Focal epithelial thinning • Disruption or absence of Bowman's layer • Normal deeper stroma
DDx• Band keratopathy: calcium deposition with a horizontal interpalpebral band; calcific plaques may stain with Alizarin red • Lattice dystrophy: amyloid deposits that stain with Congo red • Epithelial basement membrane dystrophy: irregular or thickened epithelial basement membrane with map-dot-fingerprint changes
Medical Rx• Lubricants and topical cyclosporine may relieve symptoms and control associated ocular-surface inflammation • Treat contributing conditions such as dry eye disease, blepharitis, or contact-lens overuse • Raised, visually significant, or persistently symptomatic nodules may require surgical treatment
Surgical Rx• Superficial keratectomy with or without phototherapeutic keratectomy may be used for symptomatic, visually significant, or persistent nodules • Phototherapeutic keratectomy can smooth residual anterior corneal irregularity after nodule removal • Topography-guided phototherapeutic keratectomy remains an evolving technique without established superiority
Recurrence• Recurrence varies with procedure, follow-up, residual stromal disease, and control of associated ocular-surface disease • Approximately 22% recurrence has been reported after superficial keratectomy • Long-term phototherapeutic keratectomy series have reported recurrence requiring repeat treatment in about 18% • Treating associated ocular-surface disease may reduce recurrence risk
Refractive planning• Phototherapeutic keratectomy may produce a refractive shift • In one long-term series, the mean change was a myopic shift of 1.5 ± 0.7 diopters • Account for the location and depth of ablation rather than applying a fixed hyperopic-shift rule
Emerging Rx• Customized phototherapeutic keratectomy and investigation of antifibrotic pathways are emerging approaches • Topical lifitegrast may be considered for selected coexisting ocular-surface disease, such as dry eye disease • Intense pulsed light may be considered for selected coexisting meibomian gland dysfunction • These approaches are not established treatments that reverse Salzmann nodules

10. Evolving Concepts & Emerging Therapies

TopicDetails
Customized / topography-assisted phototherapeutic keratectomy• Phototherapeutic keratectomy is an established treatment concept for Salzmann nodular degeneration. • Customized phototherapeutic keratectomy for focal smoothing has been described using lesion depth from optical coherence tomography (OCT) and lesion dimensions from Scheimpflug imaging. • The published approach is described as customized ablation area phototherapeutic keratectomy rather than as a standardized category termed topography-guided phototherapeutic keratectomy. • WaveLight EX500 has phototherapeutic keratectomy capability, but evidence was not found that WaveLight EX500 and Schwind Amaris specifically generate Salzmann-nodule phototherapeutic keratectomy profiles from anterior elevation maps. • Published Salzmann nodular degeneration series report improved surface regularity after debridement with phototherapeutic keratectomy. • Published Salzmann nodular degeneration series report reduced topographic irregularity after debridement with phototherapeutic keratectomy. • Published Salzmann nodular degeneration series report reduced higher-order aberrations after debridement with phototherapeutic keratectomy. • Superiority of a topography-guided profile over conventional phototherapeutic keratectomy has not been established. • One retrospective series reported a mean myopic shift of 1.5 diopters after mechanical nodule or pannus removal followed by phototherapeutic keratectomy. • Evidence that topography-guided phototherapeutic keratectomy causes less hyperopic shift than conventional phototherapeutic keratectomy is lacking.
Anti-transforming growth factor beta strategies• Transforming growth factor beta 1 (TGF-β1) is implicated in the proposed pathophysiology of Salzmann nodular degeneration: epithelial basement-membrane disruption may permit transforming growth factor beta 1 (TGF-β1) penetration into the anterior stroma. • Transforming growth factor beta 1 (TGF-β1) penetration into the anterior stroma may promote fibroblast and myofibroblast activation and extracellular-matrix deposition. • Pirfenidone has been studied experimentally in Salzmann nodular degeneration-derived corneal cell cultures. • Decorin has antifibrotic activity in broader corneal-fibrosis research, but evidence for decorin eye drops specifically in Salzmann nodular degeneration was not verified. • The available evidence is preclinical. • Clinical recurrence prevention with these topical antifibrotic strategies has not been established. • A Phase I study of these topical antifibrotic strategies has not been established.
Ciclosporin / lifitegrast: unproven prevention• Topical lifitegrast 5% (Xiidra) is a lymphocyte function-associated antigen 1 (LFA-1) antagonist. • Lifitegrast blocks the lymphocyte function-associated antigen 1 (LFA-1) / intercellular adhesion molecule 1 (ICAM-1) interaction. • Topical lifitegrast 5% is indicated for dry-eye disease. • Ciclosporin and lifitegrast may help manage coexisting ocular-surface inflammation in patients with Salzmann nodular degeneration, but a preventive effect on Salzmann nodular degeneration progression or recurrence has not been demonstrated in direct clinical studies. • Any benefit in preventing progression or recurrence remains theoretical; this is an emerging hypothesis rather than an established Salzmann nodular degeneration therapy.
Meibomian gland dysfunction connection• Patients with Salzmann nodular degeneration commonly have coexisting meibomian gland dysfunction (MGD) and ocular-surface dysfunction. • This supports an association, but does not establish causation. • Evidence does not establish that this association is stronger than previously recognised. • Treating meibomian gland dysfunction (MGD) may improve meibomian gland dysfunction (MGD) or evaporative-dry-eye outcomes. • Evidence is insufficient that thermal pulsation improves Salzmann nodular degeneration-related symptoms. • Evidence is insufficient that intense pulsed light improves Salzmann nodular degeneration-related symptoms. • Evidence is insufficient that thermal pulsation or intense pulsed light reduces the frequency of Salzmann nodular degeneration surgery. • A single Salzmann nodular degeneration case report described intense pulsed light for coexisting meibomian gland dysfunction (MGD) after superficial keratectomy, but did not establish prevention of recurrence.

11. High-Yield MCQs, Traps & Viva Questions

MCQ

Q1. A 45-year-old contact lens wearer presents with grey-white elevated sub-epithelial nodules arranged in a ring pattern in the mid-periphery. NaFl staining is NEGATIVE over the nodule apex but positive at its margins. The MOST accurate histological description of the sub-epithelial material is:

MCQ

Q2. Which statement about Bowman's layer in Salzmann Nodular Degeneration is CORRECT?

MCQ

Q3. A patient with Salzmann Nodular Degeneration undergoes superficial keratectomy. Post-operatively, she notices a +1.25D hyperopic shift. The MOST likely cause is:

MCQ

Q4. In the Indian subcontinent, the most common identifiable ETIOLOGY of Salzmann Nodular Degeneration is:

MCQ

Q5. On AS-OCT of a cornea with SND, the hyperreflective deposit is located:

MCQ

Q6. The MOST important factor to address to prevent RECURRENCE after superficial keratectomy for SND is:

MCQ

Q7. [ADVANCED TRAP] Fluorescein staining in SND shows positivity at the MARGINS but NOT the apex of nodules. The mechanism is:

12. Viva Questions

Rapid-Fire Viva Questions
Q1

Who first described this condition and in which year?

Q2

Is Salzmann nodular degeneration (SND) a primary or secondary degeneration?

Q3

Name three collagen types found in the SND nodule material.

Q4

What is the significance of alpha-smooth muscle actin (α-SMA) positivity in Salzmann nodular degeneration (SND)?

Q5

Why does sodium fluorescein (NaFl) stain NEGATIVELY over the nodule apex?

Q6

What masking agent is used during phototherapeutic keratectomy (PTK) for Salzmann nodular degeneration (SND), and why?

Q7

How does Salzmann nodular degeneration (SND) differ from band keratopathy on special stains?

Q8

What is the hyperopic shift per 12.5µm of PTK ablation?

Q9

Name an ocular-surface inflammatory condition associated with Salzmann nodular degeneration.

Q10

What is the recurrence rate after superficial keratectomy (SK) alone vs superficial keratectomy (SK) + phototherapeutic keratectomy (PTK)?

Was this helpful?

Topic complete

Continue to another topic when you are ready.

Previous topic← Pellucid Marginal Degeneration (PMD)Next topicKeratoconus